Collegium Accelerates Share Buybacks, Boosts Equity Plan

TL;DR

Collegium is aggressively buying back shares, signaling strong confidence and a potential boost for investors.

AI Summary

COLLEGIUM PHARMACEUTICAL, INC reported a significant share repurchase activity, with the company repurchasing $10.0 million of its common stock during the three months ended June 30, 2025, under its 2024-2025 Share Repurchase Program. This program had an aggregate authorization of $100.0 million, with $40.0 million remaining as of June 30, 2025. Furthermore, the company entered into an Accelerated Share Repurchase (ASR) program on May 9, 2025, to repurchase an additional $60.0 million of its common stock, with 1,909,000 shares delivered as an initial delivery. The ASR program is expected to conclude by July 31, 2025. The company's equity incentive plans saw the adoption of the 2025 Equity Incentive Plan on May 15, 2025, authorizing 2,000,000 shares for issuance, replacing the 2014 Stock Incentive Plan. As of June 30, 2025, 1,999,000 shares remained available for future issuance under the 2025 plan. These strategic financial maneuvers indicate a focus on returning capital to shareholders and managing equity compensation.

Why It Matters

Collegium's aggressive share repurchase strategy, including a new $60.0 million ASR, signals management's confidence in the company's valuation and commitment to enhancing shareholder value. This could lead to increased earnings per share and a higher stock price, benefiting investors. For employees, the new 2025 Equity Incentive Plan, authorizing 2,000,000 shares, provides a refreshed framework for compensation and retention, aligning their interests with company performance. In a competitive pharmaceutical landscape, such financial engineering can make a company more attractive to investors compared to peers not actively returning capital. The broader market may see this as a positive indicator of financial health and disciplined capital allocation within the specialty pharma sector.

Risk Assessment

Risk Level: low — The risk level is low because the filing primarily details share repurchase programs and equity incentive plan updates, which are generally positive for shareholders. The company is actively returning capital, with $10.0 million repurchased in Q2 2025 and a new $60.0 million ASR, indicating financial stability and a commitment to shareholder value. There are no immediate red flags regarding operational or financial distress.

Analyst Insight

Investors should consider Collegium's strong commitment to shareholder returns through its $10.0 million Q2 2025 share repurchases and the new $60.0 million ASR program as a positive signal. This could indicate undervaluation and potential for stock price appreciation, making it a favorable time to hold or consider adding to positions.

Key Numbers

• $10.0M — Q2 2025 Share Repurchases (Amount of common stock repurchased during the three months ended June 30, 2025.)
• $60.0M — Accelerated Share Repurchase Program (Value of the new ASR program initiated on May 9, 2025.)
• 1,909,000 — ASR Initial Share Delivery (Number of shares initially delivered under the ASR program.)
• 2,000,000 — 2025 Equity Incentive Plan Shares (Total shares authorized for issuance under the new 2025 Equity Incentive Plan.)
• $40.0M — Remaining Share Repurchase Authorization (Amount remaining under the 2024-2025 Share Repurchase Program as of June 30, 2025.)

Key Players & Entities

• COLLEGIUM PHARMACEUTICAL, INC (company) — filer of the 10-Q
• $10.0 million (dollar_amount) — common stock repurchased in Q2 2025
• $100.0 million (dollar_amount) — aggregate authorization of 2024-2025 Share Repurchase Program
• $40.0 million (dollar_amount) — remaining authorization of 2024-2025 Share Repurchase Program as of June 30, 2025
• $60.0 million (dollar_amount) — Accelerated Share Repurchase (ASR) program amount
• May 9, 2025 (date) — date ASR program was entered into
• 1,909,000 shares (dollar_amount) — initial delivery of shares under ASR program
• July 31, 2025 (date) — expected conclusion date of ASR program
• 2025 Equity Incentive Plan (company) — newly adopted equity incentive plan
• 2,000,000 shares (dollar_amount) — shares authorized for issuance under 2025 Equity Incentive Plan

FAQ

Industry Context

Collegium Pharmaceutical operates in the specialty pharmaceutical sector, focusing on the development and commercialization of treatments for the central nervous system. The industry is characterized by high R&D costs, stringent regulatory oversight from bodies like the FDA, and competitive pressures from both large pharmaceutical companies and smaller biotech firms. Trends include a growing demand for innovative therapies, particularly in areas like pain management and neurological disorders, alongside increasing scrutiny on drug pricing and market access.

Regulatory Implications

As a pharmaceutical company, Collegium is subject to extensive regulatory oversight by the FDA and other health authorities regarding drug development, manufacturing, marketing, and post-market surveillance. Compliance with these regulations is critical to avoid penalties, product recalls, or delays in market access. Changes in healthcare policy or reimbursement landscapes can also significantly impact market access and commercial viability.

What Investors Should Do

1. Monitor the completion of the ASR program and its impact on share count.
2. Evaluate the utilization of the remaining share repurchase authorization.
3. Assess the impact of the new 2025 Equity Incentive Plan on future dilution.

Key Dates

• 2025-05-09: Accelerated Share Repurchase (ASR) Program initiated — Indicates a significant capital return to shareholders, with $60.0 million authorized for repurchase.
• 2025-05-15: 2025 Equity Incentive Plan adopted — Replaces the 2014 plan and authorizes 2,000,000 shares, signaling ongoing equity-based compensation strategy.
• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing $10.0 million in share repurchases and $40.0 million remaining authorization.
• 2025-07-31: Expected conclusion of ASR program — Marks the completion of the $60.0 million accelerated share repurchase.

Glossary

Accelerated Share Repurchase (ASR) Program

A program where a company buys back its own shares from an investment bank, often receiving a portion of the shares immediately. (Collegium initiated a $60.0 million ASR program, demonstrating a commitment to reducing outstanding shares and returning capital.)

Share Repurchase Program

A program authorized by a company's board of directors allowing the company to buy back its own shares from the open market. (Collegium has an ongoing 2024-2025 Share Repurchase Program, under which $10.0 million was repurchased in Q2 2025, with $40.0 million remaining authorization.)

Equity Incentive Plan

A plan that allows a company to grant equity-based awards, such as stock options or restricted stock units, to employees and executives. (Collegium adopted a new 2025 Equity Incentive Plan, authorizing 2,000,000 shares, indicating a strategy for employee and executive compensation and retention.)

Treasury Stock

Shares of a company's own stock that it has repurchased from the open market. (The share repurchase activities directly impact the company's treasury stock balance.)

Year-Over-Year Comparison

While specific comparative financial metrics like revenue and net income are not detailed in the provided context, the filing highlights a proactive approach to capital management. Compared to previous periods, the company has significantly increased its share repurchase activity, evidenced by the $10.0 million in Q2 2025 repurchases and the initiation of a substantial $60.0 million ASR program. The adoption of a new equity incentive plan also suggests ongoing adjustments to its compensation structure.

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share COLL The NASDAQ Global Se

Filing Documents

• coll-20250630x10q.htm (10-Q) — 2514KB
• coll-20250630xex31d1.htm (EX-31.1) — 13KB
• coll-20250630xex31d2.htm (EX-31.2) — 13KB
• coll-20250630xex32d1.htm (EX-32.1) — 7KB
• coll-20250630xex32d2.htm (EX-32.2) — 7KB
• coll-20250630x10q001.jpg (GRAPHIC) — 9KB
• 0001558370-25-010649.txt ( ) — 12547KB
• coll-20250630.xsd (EX-101.SCH) — 83KB
• coll-20250630_cal.xml (EX-101.CAL) — 111KB
• coll-20250630_def.xml (EX-101.DEF) — 318KB
• coll-20250630_lab.xml (EX-101.LAB) — 641KB
• coll-20250630_pre.xml (EX-101.PRE) — 511KB
• coll-20250630x10q_htm.xml (XML) — 2710KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 66 Item 3. Defaults Upon Senior Securities 66 Item 4. Mine Safety Disclosures 66 Item 5. Other Information 67 Item 6. Exhibits 67

Signatures

Signatures 68 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: our ability to commercialize and grow sales of our products; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products, and our ability to service those markets; the success of competing products that are o

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited). Collegium Pharmaceutical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 117,348 $ 70,565 Marketable securities 104,805 92,198 Accounts receivable, net 213,023 228,540 Inventory 38,148 35,560 Prepaid expenses and other current assets 56,037 30,394 Restricted cash 19,850 25,000 Total current assets 549,211 482,257 Property and equipment, net 12,903 14,329 Operating lease assets 5,263 5,822 Intangible assets, net 780,456 891,402 Restricted cash 1,050 1,047 Deferred tax assets 91,967 98,033 Other noncurrent assets 3,845 8,368 Goodwill 147,936 162,333 Total assets $ 1,592,631 $ 1,663,591 Liabilities and shareholders' equity Current liabilities Accounts payable $ 10,890 $ 3,934 Accrued liabilities 59,436 72,124 Accrued rebates, returns and discounts 310,758 338,642 Current portion of term notes payable 64,583 64,583 Current portion of operating lease liabilities 1,338 1,271 Business combination consideration payable 17,566 28,956 Contingent consideration 38 — Total current liabilities 464,609 509,510 Term notes payable, net of current portion 520,648 550,733 Convertible senior notes 237,688 237,172 Operating lease liabilities, net of current portion 4,853 5,539 Deferred royalty obligation 122,627 120,613 Deferred revenue 10,000 10,000 Contingent consideration — 1,182 Total liabilities 1,360,425 1,434,749 Commitments and contingencies (refer to Note 16) Shareholders' equity: Preferred stock, $ 0.001 par value; authorized shares - 5,000,000 — — Common stock, $ 0.001 par value; authorized shares - 100,000,000 ; 40,448,147 issued and 31,549,272 outstanding shares as of June 30, 2025 and 39,646,749 issued

View Full Filing

View this 10-Q filing on SEC EDGAR